13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
39 檔
21.8%
According to the latest 13F quarterly dataset, Superstring Capital Management LP managed an equity portfolio of $158.4M at the end of Q2 2024, spanning 39 distinct U.S. exchange-listed positions.
During Q2 2024, Superstring Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics Inc | Stock-Healthcare | 12.81% | — | -32.73% | |
| 2 | LEGN | Legend Biotech Corp-adr | Stock-Other | 8.64% | — | — | |
| 3 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 8.21% | — | — | |
| 4 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 7.02% | — | -37.81% | |
| 5 | ETNBGBP | 89bio Inc | Stock-Other | 6.87% | — | -27.72% | |
| 6 | NKTX | Nkarta Inc | Stock-Other | 6.53% | — | -26.34% | |
| 7 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 4.70% | -1.84% | — | |
| 8 | KROS | Keros Therapeutics Inc | Stock-Other | 4.28% | — | +119.61% | |
| 9 | ACLXGBX | Arcellx Inc | Stock-Other | 4.11% | — | — | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 3.64% | — | — | |
| 11 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 3.22% | — | — | |
| 12 | ONC | Beone Medicines Ltd-adr | Stock-Other | 2.25% | +2.21% | NEW | |
| 13 | FATE | Fate Therapeutics Inc | Stock-Other | 2.06% | — | -45.97% | |
| 14 | ALLO | Allogene Therapeutics Inc | Stock-Other | 2.03% | — | +32.36% | |
| 15 | PYXS | Pyxis Oncology Inc | Stock-Other | 2.02% | — | -1.89% | |
| 16 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.83% | — | -17.70% | |
| 17 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.77% | — | +69.49% | |
| 18 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.55% | — | — | |
| 19 | TRML | Tourmaline Bio Inc | Stock-Other | 1.54% | — | +36.10% | |
| 20 | NVCR | NovoCure Limited | Stock-Healthcare | 1.44% | — | — | |
| 21 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.35% | — | — | |
| 22 | CABA | Cabaletta Bio Inc | Stock-Other | 1.32% | +0.15% | -51.89% | |
| 23 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.25% | — | — | |
| 24 | ALLKGUSD | Allakos Inc | Stock-Other | 1.19% | — | -23.76% | |
| 25 | CATX | Perspective Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 26 | SVRA | Savara Inc | Stock-Other | 1.02% | -2.39% | -90.32% | |
| 27 | BMEA | Biomea Fusion Inc | Stock-Other | 0.95% | -0.22% | — | |
| 28 | KURA | Kura Oncology Inc | Stock-Other | 0.94% | — | — | |
| 29 | ✓ | Zura Bio LTD | Stock-Other | 0.69% | — | — | |
| 30 | ATYR | Atyr Pharma Inc | Stock-Other | 0.62% | — | — | |
| 31 | PEPG | Pepgen Inc | Stock-Other | 0.59% | — | -74.43% | |
| 32 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 33 | EYPT | Eyepoint Inc | Stock-Other | 0.41% | — | — | |
| 34 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.39% | — | -53.70% | |
| 35 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 36 | ✓ | Stock-Other | 0.25% | — | — | ||
| 37 | CMPS | Compass Pathways PLC | Stock-Other | 0.25% | — | — | |
| 38 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.25% | — | — | |
| 39 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.05% | — | -82.28% |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 39 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CYTK, LEGN, 430) accounted for 21.8% of total reported equity market value during Q2 2024.
During Q2 2024, Superstring Capital Management LP's top holdings by market value included CYTK (12.8%)、LEGN (8.6%)、430 (8.2%). The largest single position, CYTK, represented 12.8% of total portfolio value.
In Q2 2024, Superstring Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.